Last reviewed · How we verify
Kenacort in orabase
Kenacort in orabase is a Small molecule drug developed by Hams Hamed Abdelrahman. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Kenacort in orabase |
|---|---|
| Sponsor | Hams Hamed Abdelrahman |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of Vitamin b12 Versus Kenalog on Traumatic Ulcer Associated With Orthodontic Treatment (NA)
- Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus (PHASE2)
- Treatment Outcomes and Patient Satisfaction of Oral Lichen Planus Treatment (PHASE2, PHASE3)
- EVR and EPO for Liver Transplant Tolerance (PHASE1)
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
- Oxygenated Gel Therapy in the Management of Oral Aphthous Ulcers (PHASE2, PHASE3)
- Evaluation of Efficacy of Neem (Azadirachta Indica) Versus Triamcinolone Acetonide in the Treatment of Oral Lichen Planus. (PHASE1, PHASE2)
- Efficacy of Coconut Gel Compared to Corticosteroid Gel in the Management of Oral Lichen Planus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kenacort in orabase CI brief — competitive landscape report
- Kenacort in orabase updates RSS · CI watch RSS
- Hams Hamed Abdelrahman portfolio CI
Frequently asked questions about Kenacort in orabase
What is Kenacort in orabase?
Who makes Kenacort in orabase?
What development phase is Kenacort in orabase in?
Related
- Manufacturer: Hams Hamed Abdelrahman — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing